Welcome to our dedicated page for Paragon 28 news (Ticker: FNA), a resource for investors and traders seeking the latest updates and insights on Paragon 28 stock.
Paragon 28 Inc (FNA) is a leading innovator in foot and ankle orthopedic devices, specializing in surgical solutions that enhance patient outcomes. This news hub provides investors and healthcare professionals with essential updates on the company’s financial performance, product developments, and industry leadership.
Access real-time announcements including quarterly earnings reports, FDA-cleared device launches, and strategic partnerships with surgical institutions. Our curated collection features regulatory milestones, clinical trial results, and executive commentary – all critical for understanding FNA’s position in the $5B+ global foot and ankle device market.
Key updates cover innovative implant systems, surgeon training initiatives, and manufacturing expansions that demonstrate Paragon 28’s commitment to advancing orthopedic care. Bookmark this page for verified updates on procedural innovations like fracture fixation solutions and deformity correction technologies.
Paragon 28, Inc. (NYSE: FNA), a leading medical device company focused on foot and ankle orthopedics, will participate in a fireside chat at the Bank of America Securities 2023 Healthcare Conference on May 10, 2023, at 5:20 p.m. ET. The event will feature
Based in
Paragon 28, Inc. (NYSE: FNA) has launched its innovative Phantom® Metatarsal Shortening System, designed for in-line shortening osteotomies of the lesser metatarsals, which treat common foot ailments like metatarsalgia and floating toe. The system features a patent-pending cut guide for enhanced precision. CEO Albert DaCosta emphasized the system's potential to drive growth in the forefoot segment, complementing the company's existing portfolio, including TenoTac™ and HammerTube™. The launch aims to provide a comprehensive solution for surgeons addressing forefoot conditions.
Contributors to the design include renowned surgeons, underscoring the system's innovative approach to improving patient outcomes in foot and ankle orthopedic procedures.
Paragon 28, Inc. (NYSE: FNA), a prominent medical device company focusing on the foot and ankle orthopedic market, will announce its first quarter 2023 financial results on May 4, 2023, after market close. A conference call is scheduled for 4:30 p.m. ET, providing insights into the company's financial performance and future outlook. Investors can join the call by dialing (833-470-1428) domestically or (929-526-1599) internationally, using conference ID: 007721. The event will also be webcasted live on the company's investor website, with a replay available for 90 days. Paragon 28 is dedicated to enhancing patient care through innovative orthopedic solutions for various foot and ankle conditions, aiming to improve surgical outcomes and reduce complications.
Paragon 28, Inc. (NYSE: FNA) reported its financial results for Q4 and full year 2022, showcasing a strong revenue performance.
Q4 consolidated net revenue reached $51.5 million, marking a 20.4% increase. For the full year, consolidated net revenue totaled $181.4 million, up 23%. U.S. revenue for Q4 was $45.3 million, contributing to a 22% annual growth rate. The gross margin remained robust at 82% for both Q4 and the entire year.
However, the company faced a net loss of $38.8 million for Q4, up from a loss of $6.2 million in the prior year, and an annual loss of $67.3 million.
Looking ahead, Paragon 28 anticipates net revenue of $214-$218 million for 2023, indicating an 18%-20% growth.
FAQ
What is the current stock price of Paragon 28 (FNA)?
What is the market cap of Paragon 28 (FNA)?
